RANKL-independent modulation of osteoclastogenesis

Lee, 2015, Periodontitis mainly increases osteoclast formation via enhancing the differentiation of quiescent osteoclast precursors into osteoclasts, J Periodontal Res, 50, 256, 10.1111/jre.12203 Schett, 2009, Osteoimmunology in rheumatic diseases, Arthritis Res Ther, 11, 210, 10.1186/ar2571 Boyce, 2008, Functions of RANKL/RANK/OPG in bone modeling and remodeling, Arch Biochem Biophys, 473, 139, 10.1016/j.abb.2008.03.018 Massey, 1999, Human osteoclasts derive from CD14-positive monocytes, Br J Haematol, 106, 167, 10.1046/j.1365-2141.1999.01491.x Mochizuki, 2006, Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-κB ligand, J Immunol, 177, 4360, 10.4049/jimmunol.177.7.4360 Lewinson, 1995, Ontogenesis of chondro/osteoclasts and their precursors in the mandibular condyle of the mouse, Bone, 17, 293, 10.1016/8756-3282(95)00214-X Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X Kudo, 2002, Proinflammatory cytokine (TNFα/IL-1α) induction of human osteoclast formation, J Pathol, 198, 220, 10.1002/path.1190 Ohshima, 1998, Interleukin 6 plays a key role in the development of antigen-induced arthritis, Proc Natl Acad Sci USA, 95, 8222, 10.1073/pnas.95.14.8222 Uy, 1995, Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo, Endocrinology, 136, 3207, 10.1210/endo.136.8.7628353 Kogawa, 2010, The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts, J Steroid Biochem Mol Biol, 121, 277, 10.1016/j.jsbmb.2010.03.048 Souza, 2013, The role of cytokines in inflammatory bone loss, Immunol Investig, 42, 555, 10.3109/08820139.2013.822766 Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852 Jimi, 1999, Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function, J Immunol, 163, 434, 10.4049/jimmunol.163.1.434 Khosla, 2001, Minireview: the OPG/RANKL/RANK system, Endocrinology, 142, 5050, 10.1210/endo.142.12.8536 Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 Min, 2000, Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis, J Exp Med, 192, 463, 10.1084/jem.192.4.463 Mizuno, 1998, Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin, Biochem Biophys Res Commun, 247, 610, 10.1006/bbrc.1998.8697 Boyle, 2003, Osteoclast differentiation and activation, Nature, 423, 337, 10.1038/nature01658 Xing, 2002, NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis, J Bone Miner Res, 17, 1200, 10.1359/jbmr.2002.17.7.1200 Franzoso, 1997, Requirement for NF-κB in osteoclast and B-cell development, Genes Dev, 11, 3482, 10.1101/gad.11.24.3482 Li, 2002, p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function, Endocrinology, 143, 3105, 10.1210/endo.143.8.8954 Wong, 1999, TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src, Mol Cell, 4, 1041, 10.1016/S1097-2765(00)80232-4 David, 2002, JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms, J Cell Sci, 115, 4317, 10.1242/jcs.00082 Grigoriadis, 1994, c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling, Science, 266, 443, 10.1126/science.7939685 Takayanagi, 2002, Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts, Dev Cell, 3, 889, 10.1016/S1534-5807(02)00369-6 Ishida, 2002, Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator, J Biol Chem, 277, 41147, 10.1074/jbc.M205063200 Kobayashi, 2000, Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, J Exp Med, 191, 275, 10.1084/jem.191.2.275 Azuma, 2000, Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts, J Biol Chem, 275, 4858, 10.1074/jbc.275.7.4858 Kim, 2005, Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis, J Exp Med, 202, 589, 10.1084/jem.20050978 Gravallese, 2001, The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption, Arthritis Res, 3, 6, 10.1186/ar134 Kanazawa, 2005, TRAF2 is essential for TNF-α-induced osteoclastogenesis, J Bone Miner Res, 20, 840, 10.1359/JBMR.041225 Li, 2000, RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism, Proc Natl Acad Sci USA, 97, 1566, 10.1073/pnas.97.4.1566 Wei, 2005, IL-1 mediates TNF-induced osteoclastogenesis, J Clin Investig, 115, 282, 10.1172/JCI200523394 Shim, 2018, Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications, Calcif Tissue Int, 102, 533, 10.1007/s00223-017-0373-1 Nakamura, 2006, Regulation of osteoclast differentiation and function by interleukin-1, Vitam Horm, 74, 357, 10.1016/S0083-6729(06)74015-8 Kowalski, 2006, Clinical state of the patients with periodontitis, IL-1 polymorphism and pathogens in periodontal pocket--is there a link? (An introductory report), Adv Med Sci, 51, 9 Jimi, 1999, Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells, Exp Cell Res, 247, 84, 10.1006/excr.1998.4320 Kitazawa, 1994, Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice, J Clin Investig, 94, 2397, 10.1172/JCI117606 Lorenzo, 1998, Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy, Endocrinology, 139, 3022, 10.1210/endo.139.6.6128 Fuller, 2006, Murine osteoclast formation and function: differential regulation by humoral agents, Endocrinology, 147, 1979, 10.1210/en.2005-1340 Tanabe, 2005, IL-1α stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts, Life Sci, 77, 615, 10.1016/j.lfs.2004.10.079 Akatsu, 1991, Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro, J Bone Miner Res, 6, 183, 10.1002/jbmr.5650060212 Ma, 2004, Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α, Cytokine, 26, 138, 10.1016/j.cyto.2004.02.001 Kim, 2009, The mechanism of osteoclast differentiation induced by IL-1, J Immunol, 183, 1862, 10.4049/jimmunol.0803007 Girasole, 1995, Interleukin-6: a pathogenetic role in the postmenopausal osteoporosis?, Acta Biomed Ateneo Parm, 66, 125 Roodman, 2001, Studies in Paget's disease and their relevance to oncology, Semin Oncol, 28, 15, 10.1016/S0093-7754(01)90227-1 Wong, 2006, Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis, Arthritis Rheum, 54, 158, 10.1002/art.21537 Udagawa, 1995, Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors, J Exp Med, 182, 1461, 10.1084/jem.182.5.1461 Tamura, 1993, Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6, Proc Natl Acad Sci USA, 90, 11924, 10.1073/pnas.90.24.11924 Kudo, 2003, Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism, Bone, 32, 1, 10.1016/S8756-3282(02)00915-8 Yoshitake, 2008, Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways, J Biol Chem, 283, 11535, 10.1074/jbc.M607999200 Duplomb, 2008, Interleukin-6 inhibits receptor activator of nuclear factor κB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3, Endocrinology, 149, 3688, 10.1210/en.2007-1719 Feng, 2017, Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways, Sci Rep, 7, 41411, 10.1038/srep41411 Heymann, 2000, gp130 cytokine family and bone cells, Cytokine, 12, 1455, 10.1006/cyto.2000.0747 Girasole, 1994, Interleukin-11: a new cytokine critical for osteoclast development, J Clin Investig, 93, 1516, 10.1172/JCI117130 Manolagas, 1995, New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130, Int J Immunopharmacol, 17, 109, 10.1016/0192-0561(94)00089-7 Romas, 1996, The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures, J Exp Med, 183, 2581, 10.1084/jem.183.6.2581 Nair, 1996, Bacterially induced bone destruction: mechanisms and misconceptions, Infect Immun, 64, 2371, 10.1128/IAI.64.7.2371-2380.1996 Toyomura, 2003, From lysosomes to the plasma membrane: localization of vacuolar-type H+-ATPase with the a3 isoform during osteoclast differentiation, J Biol Chem, 278 Islam, 2007, Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells, Biochem Biophys Res Commun, 360, 346, 10.1016/j.bbrc.2007.06.023 Ikebe, 2009, Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway, J Surg Oncol, 100, 725, 10.1002/jso.21392 He, 2016, TLR4-MyD88-TRAF6-TAK1 complex-mediated NF-κB activation contribute to the anti-inflammatory effect of V8 in LPS-induced human cervical cancer SiHa cells, Inflammation, 39, 172, 10.1007/s10753-015-0236-8 Suda, 2004, Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation, J Immunol, 172, 2504, 10.4049/jimmunol.172.4.2504 Sato, 2004, MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha, J Exp Med, 200, 601, 10.1084/jem.20040689 Odkhuu, 2015, Involvement of redox balance in in vitro osteoclast formation of RAW 264.7 macrophage cells in response to LPS, Innate Immun, 21, 194, 10.1177/1753425914524242 Mauri, 1998, LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator, Immunity, 8, 21, 10.1016/S1074-7613(00)80455-0 Shaikh, 2001, Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction, J Immunol, 167, 6330, 10.4049/jimmunol.167.11.6330 Kang, 2007, LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes, Arthritis Rheum, 56, 1106, 10.1002/art.22493 Edwards, 2006, LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis, Arthritis Rheum, 54, 1451, 10.1002/art.21821 Arch, 1998, Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death, Genes Dev, 12, 2821, 10.1101/gad.12.18.2821 Centrella, 1994, Transforming growth factor-β gene family members and bone, Endocr Rev, 15, 27 Pfeilschifter, 1998, Concentration of transforming growth factor beta in human bone tissue: relationship to age, menopause, bone turnover, and bone volume, J Bone Miner Res, 13, 716, 10.1359/jbmr.1998.13.4.716 Takai, 1998, Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells, J Biol Chem, 273, 27091, 10.1074/jbc.273.42.27091 Massey, 2001, Transforming growth factor-β1 (TGF-β) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment, Bone, 28, 577, 10.1016/S8756-3282(01)00432-X Itonaga, 2004, Transforming growth factor-β induces osteoclast formation in the absence of RANKL, Bone, 34, 57, 10.1016/j.bone.2003.08.008 Hemingway, 2011, RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II, Bone, 48, 938, 10.1016/j.bone.2010.12.023 Abe, 2006, BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma, Leukemia, 20, 1313, 10.1038/sj.leu.2404228 Schneider, 1999, BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth, J Exp Med, 189, 1747, 10.1084/jem.189.11.1747 Kelly, 2000, APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death, Cancer Res, 60, 1021 Sang, 2017, Analysis of the mechanism by which nerve growth factor promotes callus formation in mice with tibial fracture, Exp Ther Med, 13, 1376, 10.3892/etm.2017.4108 Grills, 1998, Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone, Acta Orthop Scand, 69, 415, 10.3109/17453679808999059 Hukkanen, 1993, Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling, Neuroscience, 54, 969, 10.1016/0306-4522(93)90588-7 Yasui, 2012, Nerve growth factor and associated nerve sprouting contribute to local mechanical hyperalgesia in a rat model of bone injury, Eur J Pain, 16, 953, 10.1002/j.1532-2149.2011.00094.x Yamashiro, 2000, Inferior alveolar nerve transection inhibits increase in osteoclast appearance during experimental tooth movement, Bone, 26, 663, 10.1016/S8756-3282(00)00282-9 Wang, 2006, Role of IGF-I signaling in regulating osteoclastogenesis, J Bone Miner Res, 21, 1350, 10.1359/jbmr.060610 Mochizuki, 1992, Insulin-like growth factor-I supports formation and activation of osteoclasts, Endocrinology, 131, 1075, 10.1210/endo.131.3.1505451 Nakao, 2009, IGF2 modulates the microenvironment for osteoclastogenesis, Biochem Biophys Res Commun, 378, 462, 10.1016/j.bbrc.2008.11.083 Traub, 2016, Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone, Eur J Cancer, 59, 1, 10.1016/j.ejca.2016.01.006